Conditions: Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer
Keywords: Ovary Ovarian Fallopian Peritoneal Cancer Gynecological Female
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 146
Healthy volunteers: no

Brief summary:
This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian cancer.

Detailed description:

Arms:
arm 1: Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days. arm 2: Perioperative administration of placebo, at same dosing interval as study drug.

Interventions: intervention 1: Alvimopan intervention 2: Placebo
Intervention descriptions: intervention 1: Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. intervention 2: Perioperative administration of placebo, at same dosing interval as study drug.

Protocol document: